---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-025688"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-08-27T23:59:59+00:00"
generated_at: "2026-05-17T09:48:55.874880+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Telomir reports in vitro data: Telomir-1 inhibits UTX and modestly targets Tankyrases

## Summary
- Telomir-1 potently inhibits UTX (KDM6A), a histone demethylase linked to cancer, aging, neurodegeneration.
- Low-level inhibition of Tankyrases (PARP5A/B) may disrupt Wnt/β-catenin pathway without telomere shortening risks.
- Selectivity vs GCN5L2 suggests cleaner safety margin vs other epigenetic drugs.
- Prior in vivo data showed reactivation of tumor suppressors STAT1/TMS1 and telomere elongation.

## SEC filing metadata
- accession: 0001641172-25-025688
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-08-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000164117225025688/0001641172-25-025688-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000164117225025688/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-025688
- JSON: https://secwatch.observer/filing/0001641172-25-025688.json
- Plain text: https://secwatch.observer/filing/0001641172-25-025688.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.